Background: Diarrhea-predominant irritable bowel syndrome (IBS-D) is a functional
recognized and various environmental factors, including diet, smoking, and stress participate in IBS progression. 3 The diagnosis is presently based on the Rome IV criteria. 2 Interestingly, IBS is mainly diagnosed in women (female/male sex ratio=2:1 in survey-based and to 4:1 in practice-based diagnostics) and its incidence increases during the early adult years. 4 The prevalence of IBS in men is almost constant within 20-70 age range; the most severe IBS symptoms in women occur from the late teenage years up to the mid 40s.
5
Gender-related differences in GI motility and visceral hypersensitivity have been broadly studied in the clinical setting and in numerous animal models. [6] [7] [8] [9] Female hormones, mainly estrogens, were found to affect visceral sensitivity, GI motility, intestinal permeability, and the immune activation of the intestinal mucosa, 8 leading to the conclusion that female sex hormones may play an important role in the pathophysiology of IBS. 10 The significance of this correlation has been further recognized by the alternation of IBS symptoms during menstrual cycle phases, pregnancy, or menopause. 11 For example, Chang et al.
reported that approx. 40% of women with IBS indicate that the menstrual cycle has an impact on IBS symptoms.
12
The physiological effects of female sex hormones on the body systems and on the regulation of GI homeostasis are predominantly moderated via specific estrogen receptors (ERs). 13 The family of ERs includes (i) nuclear ERs (ERα and ERβ) and (ii) membrane mER-Gαq, ER-X, mERα, and mERβ, 14 mediating genomic and non-genomic action of ER ligands, respectively. G protein-coupled estrogen receptor (GPER), also known as GPR30, belongs to the seven transmembrane G protein-coupled receptor (GPCR) family and presents one site, which potentially mediates the effects of estrogen on GI motility. 15 GPER is localized on the plasma membrane and on intracellular membranes, such as the endoplasmic reticulum and the Golgi apparatus. 16 It was
shown that 17β-estradiol is a highly potent agonist of GPER. Of note, the classical nuclear ERs (ERα and ERβ) appear to overlap with GPER, not only in terms of many of their cellular and physiological responses (growth, differentiation, and proliferation) but also as far as in ligandbinding properties are concerned. [17] [18] [19] To date, several ligands common for ER and GPER have been described and characterized both in vitro and in vivo; these include not only 17β-estradiol but also 4-hydroxytamoxifen and ICI182,780.
20
The higher prevalence of functional GI disorders including IBS in women suggests that female sex hormones as a potential drug target in these disorders. Therefore, the aim of our study was to assess the effect of GPER and ER ligands on the colonic motility and abdominal pain in the established mouse models. In addition, we aimed to investigate the cross talk between GPER and ER in the GI tract and to compare the possible differences between both sexes.
| MATERIALS AND METHODS

| Animals
Male and female CD1 mice (Animal Facility of the University of Calgary, Canada), weighing 20-23 g, were used for this study. The animals were housed at a constant temperature (22±1°C) and maintained under a 12-h light/dark cycle (light turned on at 6 a.m.) in cages with sawdust bedding and had free access to laboratory chow and tap water. The study was carried out in strict accordance with the institutional recommendations. All procedures used in this study were approved by the Local Ethical Committee for Animal Research (M07071) and carried out in accordance with the approved guidelines.
| Human samples
The experimental protocols were approved by the Institutional Ethics
Committee of the Institute of Experimental Research in Munich, Germany. Informed consent was obtained from all patients. All samples were obtained from macroscopically normal regions collected from patients with tumor resections during biopsies. To detect the expression of human GPER, whole mounts were immediately frozen after isolation and kept at −70°C until further processing. To perform organ bath studies, whole mounts samples were immediately placed in preoxygenated Krebs solution.
| Immunohistochemistry
Cryosections of the human colon preparations collected during colonoscopy and mouse ileum samples were used for immunohistochemistry. Briefly, tissue was fixed for 2 h at room temperature in 4% paraformaldehyde solution, then rinsed 3-5 times with PBS and transferred to a 30% sucrose solution for 24 h. The tissue was then embedded in OCT-embedding medium, sectioned at 10 μm, and thawmounted on polylysine-coated slides. Endogenous biotin was blocked using an avidin/biotin blocking kit (Zymed; Invitrogen, Merelbeke, Belgium). All primary and secondary antibodies were diluted in PBS containing 10% normal goat serum, 0.01% bovine serum albumin, 0.05% thiomerosal, and 0.01% sodium azide (reffered as PBS). Tissue fragments were then preincubated for 1 h in PBS containing 1%
Triton X-100 and subsequently the sections were exposed to: rabbit anti-GPER (#Ab 39742; 1:200; Abcam, Cambridge, MA, USA), guinea pig anti-NOS (#B-GP 2251, 1:1000; EuroDiagnostica, Arnhem, The Netherlands) overnight at room temperature. To detect immunoreactivity, the following secondary antibodies were used: biotinylated
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• The stimulation of G protein-coupled estrogen receptor and estrogen receptors is involved in the regulation of the GI motility and visceral pain.
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donkey anti-rabbit antibody (1:100), Cy3-conjugated donkey antiguinea pig (1:800), FITC-conjugated Streptavidin (1:100). Additionally, human tissues were stained with 4′,6-Diamidino-2-phenylindole (DAPI) before visualization with a microscope.
Negative controls (primary antibody was omitted) and specificity controls with antigen-antibody preabsorption were performed. The slides were examined under a Zeiss Axiovert fluorescence microscope and images were taken with a Zeiss LSM510 confocal system (Jena, Germany). Brightness and contrast of the images were adjusted using Adobe Photoshop (San Jose, CA, USA).
| In vitro organ bath studies
All experiments were performed as described earlier. was applied by a S88X stimulator (Grass Technologies), and delivered through electrodes placed around the tissue.
Before the addition of drugs, the mean amplitude of three twitch contractions was expressed, and treated as an internal control. Changes in contractions were reported as the percentage of the internal control.
G-1, a potent and selective GPER agonist or 17β-estradiol (100 nM- 
| Tissue preparation for electrophysiological experiments
Mice were killed by cervical dislocation and the proximal colon was 
| Intracellular electrical recording
Intracellular recordings of circular smooth muscle cells of the colon were performed as described previously. 22 To minimize muscular contraction, guanethidine and nifedipine (both 1 μM) were added. 
| In vivo studies
Colonic bead expulsion test
The distal colonic expulsion test was performed as described recently. 23 Briefly, animals were fasted overnight (for maximum 16 h);
tested compounds (G-1 or 17β-estradiol) or vehicle were administered in the final volume 0.1 mL, intravenously (i.v.) and 5 min later, a prewarmed (37°C) glass bead (diameter: 2 mm) was placed into the distal colon using a silicone pusher. After insertion of the bead, mice were transferred to clear plastic cages (20×20×15 cm) on a white sheet, and the time to bead expulsion was measured. Mice, which did not expel the bead within 30 min were killed to confirm the presence of the bead in the colon.
Mouse model of hypermotility
The mouse model of hypermotility was induced by introduction to a new environment, which caused acute stress as described earlier. 24 To test the effect of G-1 on stress-induced defecation, non-fasted ani- 
| Data analysis and statistics
The results are expressed as mean±SEM. Statistical analysis was performed using Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA).
ANOVA followed by Newman-Keuls post hoc test was used for multiple comparisons. P-values <.05 were considered as statistically significant. Values given with n refer to the number of experiments performed in tissues from different animals or to the number of animals in the group.
| RESULTS
| Immunohistochemical staining of GPER in humans
G protein-coupled estrogen receptor was present in the myenteric plexus in the ascending and descending colon, where nerve fibers were clearly stained ( Figure 1A ). In addition, GPER-positive cells were found in the most outer layer of mesothelial cells of the tunica serosa.
Double staining of GPER with a nitrergic marker revealed not clear coexpression of GPER with neuronal nitric oxide synthase (nNOS) in the human colon. Moreover, nuclear staining for GPER was absent in the human tissue. Finally, there are no differences between the localization of GPER in the female or male tissue ( Figure 1A ).
| Immunohistochemical staining of GPER in mice
Immunohistochemical staining of GPER showed that the large majority of the myenteric neurons in mice express GPER (Figure 2A ). We did not find a specific co-localization of GPER with nNOS in neurons.
GPER was also detected in non-neuronal populations of cells. The GPER expression pattern was similar in the ileum and the colon. The strongest staining of GPER in mice was observed in the nuclei of the neuronal cells. There were no obvious differences in GPER expression between the tissue of the female or the male animals.
| Inhibition of smooth muscle contractility by G-1 and 17β-estradiol in human colon
The influence of G-1 and 17β-estradiol on the smooth muscle contraction in the human colon was characterized in the organ bath studies. In this setup, G-1 inhibited colonic contractility induced by EFS stimulation; the most potent effect of G-1 was observed at the concentration 1 μM ( Figure 1B) . Concurrently, 17β-estradiol inhibited EFS-induced twitch contractions in the colon in a concentration-dependent manner; the latter effect was statistically significant ( Figure 1C ).
| Inhibition of smooth muscle contractility by G-1 and 17β-estradiol in mouse colon
To further characterize the involvement of the ERs GPER, ERα and ERβ on smooth muscle contractility in the mouse colon, organ bath studies on isolated mouse tissue segments were performed. To assess the role of GPER in colon contractility, a selective GPER agonist, G-1 and 17β-estradiol, which possess high binding affinity to GPER, ERα and ERβ were used. Both compounds alone did not modify the basal tonus or spontaneous phasic activity (data not shown). G-1 inhibited the EFSinduced twitch contractions in the colon in a concentration-dependent manner (100 nM-3 μM). This effect was completely reversed by G-15, a selective GPER antagonist. 17β-Estradiol also inhibited colonic contractility, but its effect was not reversed by G-15 ( Figure 2B ).
To induce myogenic contraction, isolated tissue segments were challenged with bethanechol (10 μM), the muscarinic receptor agonist to mimic the effect of acetylcholine, the major neurotransmitter found in the GI tract. Bethanechol stimulates smooth muscle cells directly and independently of the enteric nervous system. Both compounds, G-1 and 17β-estradiol, impaired the contraction amplitudes to bethanechol, indicating at direct effect of both agonists on smooth muscle contractility. G-15 reversed the inhibitory effect induced by G-1, but not by 17β-estradiol ( Figure 2B ).
To assess the effect of ERα on the colonic contractility, a selective ERα antagonist MPP was used. MPP did not reverse the inhibitory effect of G-1 on EFS-induced colonic contractility, indicating that the latter did not act through ERα. The inhibitory effect of MPP on 17β-estradiol was observed at the concentration of 1 μM, but not at 3 μM.
The effect of G-1 and 17β-estradiol on bethanechol-induced contractions was partially reversed by MPP, although it was not statistically significant ( Figure 2C ).
Finally, to characterize the role of ERβ, a selective of ERβ antagonist PHTPP was used. PHTPP did not block the inhibitory action of G-1 or 17β-estradiol on the colon contractility induced by EFS and bethanechol ( Figure 2D ).
| G-1 reduces excitatory junction potentials in the mouse colon
The amplitudes of the junction potentials (JPs) were measured in millivolts (mV) and compared to the membrane potential before application of the electrical stimulus. EFS was used to stimulate enteric The increasing concentrations of G-1 (10 nM-10 μM) led to a significant reduction in EJP in a concentration-dependent manner in the mouse distal colon. The fIJP and sIJP were not affected by G-1 (Figure 3 ).
| In vivo effects of G-1 and 17β-estradiol on colonic motility
To further characterize the involvement of ERs in GI motility in vivo, the colonic bead expulsion test was performed. G-1, administered at the dose of 20 mg/kg (i.v.) significantly prolonged the time to bead expulsion in females ( Figure 4A ). This inhibitory effect was reversed by G-15, MPP, and PTHPP suggesting the involvement of all ER subtypes in the colonic motility.
17β-Estradiol (20 mg/kg, i.v.) inhibited the time to bead expulsion in females. This effect was reversed by G-15 and MPP, but not by PHTPP ( Figure 4B ).
To exclude gender-related difference, the same experiment was performed in males. A potent inhibitory activity of G-1 (20 mg/kg, i.v.)
was observed in the colon ( Figure 4C ).
| In vivo effects of G-1 on hypermotility in mice
The effect of G-1 was further tested in pathophysiological-like conditions in the mouse model of hypermotility. G-1 (20 mg/kg, i.v.) inhibited GI motor hyperactivity in mice exposed to the novel environment and this effect was observed in both, females and males. The action of G-1 was reversed by G-15 ( Figure 5 ).
| In vivo effects of G-1 and 17β-estradiol on abdominal pain
The antinociceptive effect of G-1 and 17β-estradiol was assessed in the mouse model of visceral pain, induced by intracolonic injection of 
| DISCUSSION
Because IBS occurs up to four times more frequent in women compared to men, it was proposed that sex hormones may be implicated in IBS prevalence. In a meta-analysis of 22 studies, Simren et al. reported that women complained about severe abdominal pain, constipation, and bloating. In addition, extraintestinal symptoms and lower quality of life were reported more frequently in women. 25, 26 However, no gender differences in stool frequency, bowel habit dissatisfaction, frequency, and severity of abdominal pain were observed. 26 Considering these differences in the IBS prevalence, severity of symptoms and disease course, our study was designed to elucidate the role of the ERs: GPER, ERα, and ERβ in GI motility and abdominal pain in the mouse models mimicking IBS-D using the following pharmacological tools: a selective GPER agonist -G-1, a non-selective ER agonist, 17β-estradiol and their respective antagonists namely G-15
(GPER antagonist), MPP (ERα antagonist), and PHTPP (ERβ antagonist). In our study, we did not use ovariectomized animals although they constitute a good model to study a role of sex hormones in the numerous diseases development. However, ovariectomized animals exert a slow developing and persistent hyperalgesic state localized to the abdomen 27 and the visceromotor response to colorectal distention is different in ovariectomized and cycling animals. 28 To exclude supra-physiologic effect of estrogen, we used both female and male mice in this study.
Earlier reports revealed that ERs are highly expressed in the GI tract, on the enteric neurons, enteric glial cells, and smooth muscles. 29 Estrogen receptor β is preferentially expressed on the colonic epithelial cells and may thus affect secretion and absorption. 30 Dun from rats. 31 We report that GPER is expressed in the human colon.
The staining was present in the myenteric plexus, where nerve fibers were clearly stained and in the submucosal nerve bundles.
Supporting the relevance of our mouse-based study for human situation, the expression of GPER was also found in blood vessels 32 (in endothelial cells and more obviously in the vascular tunica media) and in smooth muscle cells (blood vessel wall, lamina muscularis mucosa, and tunica muscularis). We also showed that GPER is ex- Neuron-derived NO plays a major role in mediating non-adrenergic, non-cholinergic relaxation and thus is implicated in the regulation of GI motility by acting as an inhibitory neurotransmitter at neuromuscular junctions in the enteric nervous system. 34 Li et al. showed that G-1 increased production of NO in mouse longitudinal muscle myenteric plexus preparations, indicating that GPER triggers NO production and thus influences GI motility. 15 Interestingly, it was suggested that NO-mediated decrease in GI motility might be also mediated by 17β-estradiol, 35 pointing to a crucial role of ERs in the proper production Estrogen receptors are highly involved in GI motility. 37 We found that G-1 inhibited bethanechol-and EFS-induced colonic contractions.
The inhibitory action on the colonic motility of G-1 was mainly mediated by GPER, ERα, and ERβ. These findings are in line with the results of the study performed by Li et al., 15 who demonstrated an inhibitory effect of G-1 on bethanechol-induced contractions via neurogenic mechanism and with those reported by Ravella et al., who observed slower gastric emptying and reduced nitrergic relaxation in mice with decreased expression of ERα, indicating that ERα affected GI function. 38 We also characterized an inhibitory effect of 17β-estradiol on the bethanechol-and EFS-induced contractions in the female mouse colon. This action was partially mediated by ERα, while ERβ or GPER did not participate in this inhibition. In earlier studies, it was evidenced that 17β-estradiol inhibited bethanechol-induced contractions in the rat ileum. 39 Moreover, Hogan et al. 40 showed that 17β-estradiol inhibited human colonic motility induced by bethanechol and its effect was dependent on a non-genomic cell membrane receptor mechanism. Moreover, they showed that N(ω)-propyl-l-arginine, a selective nNOS inhibitor attenuated the inhibitory effect of G-1 on bethanechol-induced contractions, what suggested the involvement of nNOS in neurogenic NO pathway. Our electrophysiological experiments showed that G-1 inhibited the cholinergic excitatory neuronal pathway, but had no effect on purinergic and nitrergic inhibitory transmission -suggesting a multifactorial action of GPER stimulation in GI system.
In the in vivo studies, G-1 inhibited colonic motility not only through GPER, but also through ERα and ERβ, indicating that both, classical ER and GPER, are crucial in the maintenance of GI motility. Importantly, GPER activation caused the same effect in both genders. We further showed an inhibitory effect of 17β-estradiol on colonic bead expulsion through GPER and ERα, whereas ER β was not involved in colonic motility. In parallel, Li et al. 15 showed that 17β-estradiol prolonged colonic motility through GPER.
The possibility of a cross talk between ERs should always be taken into consideration. 41 We observed slightly different effects in vitro and in vivo, indicating functional plasticity of classical and novel ERs.
Homo-or heterodimers (ERβ-ERβ or ERα-ERβ) may be formed and thus involved in GI motility. The interaction of GPER with ER could also explain different results from both in vitro and in vivo studies. G-1 could induce also ER activation and then alter the expression, function of ER or cause internalization.
Estrogen receptor α and β have been shown to be strongly implicated in the regulation of visceral pain by several factors, including estrogens. 42 Estrogen receptor α is expressed predominantly in the superficial dorsal horn, which receives information from nociceptive sensory neurons, while ERβ is found in deeper layers, what implies a different function for both ER in visceral pain. 43 In another study, it was found that ERα, ERβ, and GPER, were expressed in the spinal cord dorsal horn without sex specificity; moreover, all of them were present in the membrane and cytosolic protein fractions, which strongly supports that all ERs are crucial in pain signaling. 44 Finally, it was evidenced in numerous animal studies that visceral and somatic sensitivity vary over the rat estrous cycle and high levels of ovarian hormones are associated with hypersensitivity. 45 In humans, experimental pain was increased or decreased, and there were no changes in pain responsiveness during the menstrual cycle or during hormone replacement therapy. 46 We evidenced for the first time that G-1 exerted an antinociceptive action through GPER, but also through ERα; ERβ was not implicated in visceral pain. Moreover, we found that 17β-estradiol had an analgesic activity and its action was mediated by GPER without affecting classical ER. Finally, G-1 was more potent analgesic agent in comparison with 17β-estradiol. The antinociceptive effects of GPER and ER agonists could also be described by their potential anti-inflammatory effects, however, this needs further investigation.
Previous studies revealed that ERα activation using 4,4′,4′′- to CRD 4 h after injection suggesting that a membrane-initiated signaling pathway was not involved. In another study, 17β-estradiol facilitated the visceromotor response to CRD within 15 min, suggesting activation of membrane-initiated signaling. 48 Moreover, it was revealed that a single injection of estrogen mimicked natural cycling and is appropriate for studying estrogen modulation of pain in rats. 
